Soft Tissue Allografts Market Regional Analysis:
North American Market Insights
North America region is anticipated to hold over 44.2% market share by 2035. The growth of the market can be attributed majorly to the rising prevalence of arthritis, and rising healthcare expenditure on its treatment. In the United States, around 59 million adults, or approximately 24% of the population, suffer from arthritis. Osteoarthritis is the most prevalent type of arthritis. Gout and lupus are further kinds. Moreover, the annual cost of medical care for arthritis is around USD 300 billion. In addition to this, the surging need for rheumatoid arthritis treatment is another substantial factor that is estimated to boost the market growth further in the region over the projected time frame.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of soft tissue allografts is assessed at USD 5.32 Billion.
The global soft tissue allografts market size was valued at around USD 5.04 Billion in 2025 and is projected to grow at a CAGR of more than 6.2%, reaching USD 9.2 Billion revenue by 2035.
North America’s soft tissue allografts market will hold around 44.2% share by 2035, driven by rising prevalence of arthritis and associated healthcare expenditure.
Key players in the market include Stryker Corporation, ALON SOURCE GROUP, CONMED Corporation, LifeSciences Corporation, Organogenesis Inc., RTI Surgical, Inc., MIMEDX, Inc., Xtant Medical Holdings, Inc., Globus Medical, Inc., Bone Bank Allografts.
